Clivunel Inc Drug Patent Portfolio
Clivunel Inc owns 1 orange book drug protected by 2 US patents Given below is the list of Clivunel Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8334265 | Method of treatment of photodermatoses | 11 Mar, 2029 | Active |
| US10076555 | Methods of inducing melanogenesis in a subject | 11 Feb, 2025 | Active |
Latest Legal Activities on Clivunel Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Clivunel Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 10 Jun, 2024 | US8334265 |
|
Patent Term Extension Certificate
Critical
| 25 May, 2023 | US8334265 |
| Notice of Final Determination -Eligible | 17 Apr, 2023 | US8334265 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US8334265 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 Mar, 2022 | US10076555 |
| transaction for FDA Determination of Regulatory Review Period | 04 Nov, 2021 | US8334265 |
| transaction for FDA Determination of Regulatory Review Period | 22 Oct, 2021 | US8334265 |
| Second letter to regulating agency to determine regulatory review period | 31 Mar, 2021 | US8334265 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 Jun, 2020 | US8334265 |
| Letter from FDA or Dept of Agriculture re PTE application | 26 May, 2020 | US8334265 |
| Initial letter Re: PTE Application to regulating agency | 26 Feb, 2020 | US8334265 |
|
Email Notification
Critical
| 10 Jun, 2019 | US8334265 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Jun, 2019 | US8334265 |
|
Correspondence Address Change
Critical
| 06 Jun, 2019 | US8334265 |
|
Recordation of Patent Grant Mailed
Critical
| 18 Sep, 2018 | US10076555 |
Clivunel Inc's Family Patents
Clivunel Inc drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 14.6% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Clivunel Inc Drug List
Given below is the complete list of Clivunel Inc's drugs and the patents protecting them.
1. Scenesse
Scenesse is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8334265 | Method of treatment of photodermatoses |
11 Mar, 2029
(4 years from now)
| Active |
| US10076555 | Methods of inducing melanogenesis in a subject |
11 Feb, 2025
(3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Scenesse's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List